Table 2. Comparison of a History of a Visual Acuity of 20/200 or Worse in Childhood Uveitis.
| Characteristics N = 85 unless otherwise specified N (%) unless otherwise specified |
VA of 20/200 or worse | p-value | |
|---|---|---|---|
| Yes N=27 (31.8%) |
No N=58 (68.2%) |
||
| Demographics | |||
| Age at most recent visit, Median (25th – 75th) |
11.9 (9.1 – 15.7) |
11.4 (8.3 – 14.8) |
0.329 |
| Gender, female | 18 (66.7%) | 44 (75.9%) | 0.435 |
| Race | |||
| Caucasian | 5 (18.5%) | 46 (79.3%) | <0.001b |
| African American | 19 (70.4%) | 7 (12.1%) | |
| Other | 3 (11.1%) | 5 (8.6%) | |
| Hispanic | 2 (7.4%) | 8 (13.8%) | 0.074 |
| Insurance | |||
| Private | 13 (48.2%) | 36 (62.1%) | 0.466 |
| Medicaid | 13 (48.2%) | 21 (36.2%) | |
| None | 1 (3.7%) | 1 (1.7%) | |
| Disease Characteristics | |||
| Type of uveitis | |||
| JIA-associated uveitis | 9 (33.3%) | 38 (65.5%) | 0.009 |
| Age at uveitis diagnosis (years), Median (25th – 75th) |
6.6 (4.8 – 9.0) |
6.0 (3.5 – 11.8) |
0.728 |
| Location of Disease a (N = 82) | |||
| Anterior | 17 (65.4%) | 44 (78.6%) | 0.204 |
| Intermediate | 2 (7.7%) | 3 (5.4%) | 0.682 |
| Posterior/Panuveitis | 3 (11.5%) | 1 (1.8%) | 0.056 |
| Unknown | 4 (15.4%) | 8 (14.3%) | 0.897 |
| Bilateral Disease a (N = 80) | 21 (77.8%) | 37 (69.8%) | 0.453 |
| Type of Complications | |||
| Cataracts | 21 (77.8%) | 15 (25.9%) | <0.001b |
| Glaucoma/ocular hypertension | 10 (37.0%) | 4 (6.9%) | 0.001b |
| Synechiae | 19 (70.4%) | 19 (32.8%) | 0.002b |
| Band keratopathy | 17 (63.0%) | 10 (17.2%) | <0.001b |
| Cystoid macular edema | 14 (51.9%) | 8 (13.8%) | <0.001b |
| Initial Ocular Exam a | |||
| ≥1+ cells at first exam (N=45) | 6 (60.0%) | 22 (62.9%) | 1.000 |
| LogMAR Visual acuity (N=42) Median (25th – 75th) |
0.40 (0.18 – 1.00) |
0.18 (0.00 – 0.30) |
<0.001b |
| Labs a | |||
| ANAc positive (N=84) | 12 (46.2%) | 22 (37.9%) | 0.631 |
| Earliest ESRd (N=80) Median (25th – 75th) |
7.0 (2.0 – 16.0) |
17.0 (7.0 – 36.0) |
0.002b |
| HLAf-B27 positive (N=56) | 4 (22.2%) | 10 (26.3%) | 1.000 |
| Medication Use a (N = 84) | |||
| Methotrexate Oral | 14 (51.9%) | 38 (66.7%) | 0.232 |
| Methotrexate Subcutaneous | 21 (77.8%) | 42 (73.7%) | 0.791 |
| Infliximab | 13 (48.2%) | 14 (24.6%) | 0.045b |
| Adalimumab | 4 (14.8%) | 13 (22.8%) | 0.563 |
a
Indicates missing data;
b
p = <0.05; Chi-square tests, two sample t-tests, non-parametric test (Mann Whitney-U or Kolmogorov-Smirnov test).
c
ANA = Antinuclear antibody.
d
ESR = Erythrocyte Sedimentation Rate.
e
HLA = Human Leukocyte Antigen.